CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Razia RahmanMuhammed H RahamanAdrienne R HansonNicholas ChooJianling XieScott L TownleyRaj ShresthaRamin HassankhaniSaiful IslamSusanne RammKaylene J SimpsonGail P RisbridgerGiles BestMargaret M CenteneraSteven P Balk Ganessan KichenadasseRenea A TaylorLisa M Butler Wayne D Tilley Simon J ConnMitchell G LawrenceShudong WangLuke A Selth

Published in: British journal of cancer (2024)

Our work demonstrates that CDK9 inhibition disrupts multiple oncogenic pathways and positions CDKI-73 as a promising therapeutic agent for prostate cancer, particularly aggressive, therapy-resistant subtypes.

Keyphrases

prostate cancer
radical prostatectomy
transcription factor
cell cycle
gene expression
dna methylation
cell proliferation
stem cells
bone marrow
cell therapy